Introduction
============

Hormonal contraception is widely used globally for the prevention of unintended pregnancy. However, some have postulated that hormonal contraception may increase susceptibility to HIV infection \[[@R1]--[@R3]\]. Although overall data on the association between combined hormonal contraceptive pills and HIV acquisition are limited, there appears to be no increased risk in women with use of these methods \[[@R3]\]. With injectable contraceptive use, particularly depot medroxyprogesterone acetate (DMPA), recent meta-analyses suggest a 20--70% increased risk of HIV acquisition \[[@R3],[@R4]\]. Importantly, not all studies have demonstrated a consistent link between use of DMPA and HIV risk in women, with several well designed studies finding no statistical association \[[@R5]--[@R7]\]. The World Health Organization (WHO) recognizes this important knowledge gap and encourages research to clarify the association and explore mechanisms associated with hormonal contraceptives that may underlie an increase in HIV transmission risk \[[@R8],[@R9]\].

Several local factors within the vagina may increase HIV transmission risk and mediate the association between hormonal contraception and HIV acquisition \[[@R10]\]. One potential factor is bacterial vaginosis, a condition of a polymicrobial vaginal flora with an elevated vaginal pH and divergence from a healthy lactobaccili-dominant vaginal flora \[[@R10],[@R11]\]. There is a growing body of literature supporting the role of the microbiota in altering local and systemic immune function \[[@R12]--[@R14]\]. Several studies have found that HIV acquisition increases in the setting of bacterial vaginosis and nonlactobaccili-dominant flora \[[@R15]--[@R18]\]. Although there is growing evidence of this direct association between vaginal microbiota and HIV acquisition, it is unclear if vaginal microbiota may be implicated in the noted association between hormonal contraception and HIV risk.

Most studies suggest that combined estrogen--progestin and progestin-only hormonal contraception does not increase the presence of bacterial vaginosis and some methods may even be protective against bacterial vaginosis \[[@R19]--[@R21]\]. In a recent meta-analysis, all studies reviewed showed either a statistically significant decrease or no significant difference in the incidence of bacterial vaginosis in hormonal contraceptive users whenever compared with nonhormonal contraceptive users. Whenever including the three highest quality studies, they found a 10--20% reduction in the incidence of bacterial vaginosis in combined oral contraceptive users and an 18--30% reduction in DMPA users versus nonhormonal method users \[[@R22]\]. Another meta-analysis including 55 studies reported an approximate 25% reduction in bacterial vaginosis in hormonal contraceptive users compared with nonusers, with this pattern similar for both combined estrogen--progestin and progestin-only methods \[[@R23]\]. These data suggest that alterations in the vaginal microflora with contraceptive use are not part of the mechanisms for the observed increased HIV acquisition risk with hormonal contraception.

Prior studies have evaluated the effect of herpes simplex virus (HSV) or genital tract ulcers as potential effect modifiers in the association between hormonal contraception and HIV acquisition in women \[[@R7],[@R24]\]. However, no studies to date have evaluated whether bacterial vaginosis may modify this association. Our objective was to leverage a large HIV discordant couple cohort to explore the association between hormonal contraception and HIV acquisition in women, considering bacterial vaginosis as a potential effect modifier. Our previous evaluation of the cohort did not demonstrate a significant increase in incident HIV with oral contraceptive, injectable contraceptive or contraceptive implant use. We hypothesized that we would see a different association between hormonal contraception and incident HIV in the presence of bacterial vaginosis. This hypothesized interaction between two independent potential risk factors may explain some of the inconsistencies in the literature that cloud our interpretation of hormonal contraception as a potential HIV risk factor.

Methods
=======

Study design, participants and ethics
-------------------------------------

The study is a secondary analysis of a longitudinal cohort of heterosexual HIV serodiscordant couples in which the man is HIV-positive and the woman HIV-negative (M+F−) in Lusaka, Zambia. Heterosexual married or cohabitating HIV serodiscordant couples were invited to enroll in an open cohort study between 1994 and 2012. The study recruitment \[[@R25],[@R26]\], intervention design, uptake of contraception immediately after an educational intervention \[[@R27]\], impact of informed consent on knowledge and concerns about contraceptive methods \[[@R28]\], demographics of the cohort, rates of unintended pregnancy and impact of contraceptive method on unintended pregnancy \[[@R29]\], impact of the intervention on incident pregnancy \[[@R30]\], patterns of contraceptive use and discontinuation \[[@R31]\], impact of hormonal contraception on HIV acquisition risk \[[@R7]\], HIV transmission to partners \[[@R32]\], and disease progression \[[@R33]\] have been previously reported. The Institutional Review Boards at Emory University and the University of Zambia approved this study. Written informed consent was obtained from all participating couples.

Exposure of interest
--------------------

Contraceptive method used since last visit \[none/condoms only, oral contraceptive pills (OCPs\], DMPA (150 mg intramuscular dosage), copper intrauterine device (IUD), contraceptive implant (Levonorgestrel implant: Norplant, Jadelle), or permanent methods (hysterectomy/tubal ligation/vasectomy)) was recorded at baseline and 3-monthly follow-up visits. The majority of OCPs were combined pills containing both an estrogen and progestin, with progesterone-only pills being primarily prescribed to breastfeeding women until children were 6 months old or the minority of women with contraindications to estrogens. In our primary analysis, contraceptive methods were categorized as implant, injectable, or OCP versus nonhormonal (nonhormonal contraception), including none/condoms only or permanent methods. All methods were provided at the research site.

Outcome of interest
-------------------

The primary outcome evaluated any incident HIV infection among women, either linked or unlinked to the cohabiting male partner. HIV testing using rapid serologic tests was conducted at intervals of 3 months \[[@R26]\].

Baseline covariates
-------------------

At enrollment, baseline demographic data was collected including age of the man and woman, years cohabiting, monthly income, and woman\'s literacy in Nyanja. Other possible risk factors evaluated as covariates included number of previous pregnancies, number of sexual partners for the woman in the last year, and viral load (log10 copies/ml) of the positive male partner.

Time-varying covariates
-----------------------

At scheduled 3-monthly (or client-initiated interim) follow-up visits, time-varying exposures of interest were collected including time from enrollment (0--3 months reflecting prior to couples voluntary counseling and testing (CVCT) versus \>3 months, reflecting those receiving CVCT), pregnancy, self-reported sex without a condom with study partner in past 3 months, self-reported sex with a condom with study partner in past 3 months, sperm present on vaginal swab wet-prep, candida by wet-prep, vaginal discharge on exam, general vaginal inflammation on exam, sexually transmitted infection (STI; gonorrhea and/or chlamydia based on purulent endocervical discharge and/or trichomonas based on wet-prep), bilateral inguinal adenopathy (BIA) on exam, and active genital or perianal ulcers for woman in past 3 months (by self-report or examination finding).

Effect modification evaluation
------------------------------

The effect modifier of interest was a time-varying diagnosis of bacterial vaginosis. This was diagnosed by a wet-prep at baseline and at scheduled or client-initiated interim follow-up visits. Bacterial vaginosis was diagnosed with microscopy (wet-prep for clue cells, KOH prep for whiff test, and/or Gram stain) at a routine or interim visit.

Longitudinal data collection
----------------------------

Participants were provided with free outpatient care and the full range of contraceptive methods at the research clinic. Data collection varied by type and frequency of data collected over 17 years of follow-up. From 1994 to 2002, both partners were seen every 3 months and underwent physical exams including rapid plasma reagin (RPR) screening for syphilis, genital exams, and wet-prep with repeat HIV testing of the HIV-- partner. After 2002, physical exams and wet-prep diagnoses were performed at baseline and thereafter only if signs and symptoms of infections were present. Given this change in approach to only evaluating symptomatic individuals, we restricted this analysis to 1994--2002.

Data analysis
-------------

Analyses were conducted with SAS v9.3 (Cary, North Carolina, USA). Our analytic approach was informed by recommendations for a rigorous and consistent analysis of the association of hormonal contraception and HIV acquisition described by Polis *et al.*\[[@R34]\]. This approach was used previously in our evaluation with this cohort and demonstrated no statistically significant association between hormonal contraception and HIV acquisition in women without consideration of effect modification with bacterial vaginosis \[[@R7]\]. All analyses were stratified and separately analyzed for intervals with bacterial vaginosis and intervals without bacterial vaginosis.

Couple-years of follow-up were calculated from enrollment until the couple was censored. Couples were censored whenever either partner died, the couples separated, the positive partner started anti-retroviral therapy (ART), or if either partner was lost to follow-up. HIV incidence rates for each contraceptive method type were compared with the nonhormonal contraception reference group using univariate Cox models. These rates with corresponding 95% confidence intervals (95% CI) were calculated as the number of incident infections per couple-year of follow-up, stratified by whether a women had a bacterial vaginosis infection noted at the visit prior to that study interval.

Baseline and time-varying data were described by HIV acquisition status using counts and percentages for categorical data or means and standard deviations for continuous data. These descriptive analyses were calculated across all study intervals and were stratified by bacterial vaginosis status.

Bivariate associations between baseline and time-varying covariates and outcome infection of interest were evaluated via unadjusted Cox models to generate crude hazard ratios and 95% CIs. Additional bivariate associations between these baseline and time-varying covariate were compared for the combined outcome groups (seroconverters and nonconverters) by bacterial vaginosis status.

Multivariate Cox models estimated the total effect of time-varying contraceptive method type on time to outcome infection. Covariates significantly (*P* \< 0.05) associated with the exposure and outcome of interest were considered as potential confounders. Variable multicollinearity was assessed (condition indices of 0.30 and variance decomposition proportions of 0.05 as cutoff criteria); if any two variables were found to be collinear, the variable with the weakest association with the outcome was removed. The proportional hazards assumption using Schoenfeld residuals and graphical methods \[plots of log \[−log (survival probability)\] versus log (time)\] was confirmed for time-independent covariates. Adjusted hazard ratios (aHRs) and 95% CIs are presented for covariates in the final multivariate models. For each model, contraceptive method was forced into the final multivariable models. Breslow--Day test was used to determine the significance of an interaction by time-varying bacterial vaginosis status.

Sensitivity analysis
--------------------

We ran a sensitivity analysis including all the variables included in a nonbacterial vaginosis-stratified model, we previously published on from this cohort \[[@R7]\], given potential for unidentified confounding in the smaller stratified samples. Similarly, we ran an additional analysis including all covariates in the stratified models if found to be a confounder (associated with exposure and outcome at \<0.05) in either one or both of the strata. We also ran the analysis including variables in the prior cohort evaluation \[[@R7]\] adding as covariates sperm on wet-prep and self-reported unprotected sex. We ran an analysis excluding the genital tract findings (infections and ulcerations) as confounders as bacterial vaginosis was highly correlated with several of these findings. Further, we also ran the previously published model, excluding the genital tract findings.

Results
=======

Baseline demographics and rates for seroconversion
--------------------------------------------------

Among the 564 couples, a total of 106 women seroconverted over 1137.2 couple-years of observation (Table [1](#T1){ref-type="table"}). Bacterial vaginosis was detected at 648 of 4183 study visits (15.5%). Twenty-two of the seroconversions occurred during intervals where bacterial vaginosis was detected at the visit prior to the seroconversion and 84 during intervals without bacterial vaginosis detected. Among the 4183 visits, implants were used at 17 visits (0.4%), injectable methods at 373 visits (8.9%), OCPs at 568 visits (13.6%) and nonhormonal methods at 3225 visits \[77.1%, with copper IUD at 40 visits (0.9%), tubal ligation or vasectomy at 42 visits (1.0%) and no method or only condoms at 3143 visits (75.1%)\].

During intervals where bacterial vaginosis was detected, seroincidence rates per 100 couple-years were 8.3, 20.8, and 31.0 for nonhormonal, injectable, and OCP users, respectively. During intervals without bacterial vaginosis detected, seroincidence rates per 100-couple-years were 8.2, 9.7, and 12.3, for nonhormonal, injectable, and OCP users, respectively. No seroconversions occurred among implant users.

Bivariate analyses
------------------

Covariates significantly associated with bacterial vaginosis status included illiteracy to Nyanja (83 versus 76%), higher number of sex partners in the last year at baseline (1.09 versus 1.03), less injectable contraceptive usage (5 versus 10%), increased self-reported sex without a condom in the past 3 months (44 versus 38%), higher rates of sperm on wet-prep (24 versus 17%), increased vaginal discharge (14 versus 9%), increased STIs inflammation (15 versus 6%) and increased BIA in the woman (8 versus 7%; Table [2](#T2){ref-type="table"}).

Among intervals with bacterial vaginosis, baseline, and time-varying covariates significantly associated with HIV incidence (nonseroconverting intervals versus seroconverting intervals) included younger age of the woman (27.46 versus 22.68), OCP use (14 versus 36%), being in the initial 3 months after enrollment in CVCT cohort (2 versus 23%), vaginal inflammation (3 versus 14%) and BIA on exam (8 versus 23%) in the past 3 months. Among the intervals without bacterial vaginosis, being in the initial 3 months after enrollment in the CVCT cohort (3 versus 14%), having a STI inflammation (6 versus 13%) and BIA (7 versus 19%) in the past 3 months were associated with increased HIV incidence.

Contraceptive method at follow-up was significantly associated with seroconversion only among those with bacterial vaginosis, with an increase in seroconversion among those using OCPs compared with those using nonhormonal contraception.

Multivariate analyses
---------------------

Hormonal contraceptive method was associated with incident HIV in the multivariable analysis in the time-varying bacterial vaginosis-positive models but not in the bacterial vaginosis-negative models, where bacterial vaginosis was a significant interaction term (Breslow-Day test for interaction by bacterial vaginosis: *P* \< 0.001). In the bacterial vaginosis-positive model, when controlling for women\'s age (per year increase), vaginal inflammation in the past 3 months, and time interval since enrollment (0--3 versus 3 months), there was a significant increase in HIV acquisition among those using injectable contraception (aHR 6.55, 95% CI 1.14--37.77) and OCPs (aHR 5.20, 95% CI 1.68--16.06) compared with the nonhormonal contraception group. In the bacterial vaginosis-negative model, use of the implant, injectables, and OCPs did not have any increased hazards of HIV acquisition compared with the nonhormonal contraception group, whenever controlling for time interval since enrollment (0--3 months versus \>3 months), STI in the past 3 months, and BIA in the past 3 months (Table [3](#T3){ref-type="table"}).

Sensitivity analysis
--------------------

Overall, the results from the sensitivity analyses led to similar conclusions. In the multivariate models limited to including all the covariates that were confounders in the nonstratified evaluation previously published, we found a similar significant increase in HIV acquisition with use of injectable contraception (aHR 6.58, 95% CI 1.06--40.87) and OCPs (aHR 4.66, 95% CI 1.45--14.96) compared with nonhormonal contraception use for the bacterial vaginosis positive model. Similarly, whenever controlling for women\'s age, time interval since enrollment, vaginal inflammation, inflammatory STI, or BIA in last 3 months, the covariates that were identified as potential confounders in either or both strata, we found a similar increase in HIV acquisition with injectable (aHR 5.91, 95% CI 1.02--34.97) and OCP use. (aHR 4.78, 95% CI 1.52--15.01). Whenever excluding other genital tract findings, there was a significant increase in HIV acquisition with OCP use compared with nonhormonal contraception use (aHR 5.7, 95% CI 1.9--17.2) in the bacterial vaginosis-positive model with the association among injectable users approaching significance (aHR 5.4, 95% CI 0.96--30.4, *P* = 0.056). Whenever sperm on wet-prep and condomless sex were added to the model, a similar increase in HIV acquisition was noted with injectable (aHR 9.2, 95% CI 1.3--62.5) and OCP use (aHR 7.6, 95% CI 1.9--31.0) compared with nonhormonal contraception use in the bacterial vaginosis models. Lastly, with all the confounders from the published analysis included and excluding the genital tract findings, there was a significant increase in HIV acquisition among injectable (aHR 5.9, 95% CI 1.02--33.9) and OCP (aHR 5.6, 95% CI 1.9--17.1) users compared with nonhormonal contraception users in the bacterial vaginosis-positive model. There was no association between use of hormonal contraception and HIV acquisition in the nonbacterial vaginosis models compared with nonhormonal contraception use in any of the sensitivity analyses.

Discussion
==========

We present results indicating bacterial vaginosis as a potent effect-modifier of the association between hormonal contraception and HIV acquisition that may have large global health implications. Although increasing evidence has supported a direct role for bacterial vaginosis in increasing HIV acquisition risk, our results suggest that this impact is amplified in the setting of hormonal contraception use, specifically injectables and OCPs, with increased hazard ratios greater than 5 for HIV acquisition in the setting of bacterial vaginosis for injectables and OCPs compared with nonhormonal contraception use. Though our numbers were small and confidence intervals large, these findings highlight the importance of acknowledging the role of the vaginal environment in HIV acquisition risk and evaluating the genital tract environment in future studies investigating the association between hormonal contraceptives and HIV risk.

Proposed mechanisms for the association between hormonal contraception and HIV have included alterations in the local genital tract immunologic milieu and the composition of key HIV target immune cells, as well as alterations in vaginal epithelial tight junctions and mucosal permeability \[[@R35]--[@R37]\]. Recent evidence has pointed towards the gut microbiota and the hormonal environment as working synergistically to influence the development of disease states such as obesity, diabetes, and certain cancers \[[@R38]\]. Although a significant amount of literature has been building to explore the importance of the gut microbiota, our current understanding of the significance of the vaginal microenvironment is relatively limited. Hormonal contraception may have a differential impact to amplify the effect of the microbiota on the vaginal epithelium and immune environment. Future studies are needed to elucidate the mechanism for this interaction.

Although epidemiologic studies have not previously explored this interaction, a recent study by Fichorova *et al.*\[[@R10]\] compliments our findings. Those results demonstrated that the immunomodulatory changes attributed to different hormonal contraceptives are dependent on the genital tract microenvironment. Specifically, they report an increase in RANTES (Regulated upon Activation, Normal T-cell Expressed, and Secreted), a chemokine that has been associated with increased HIV acquisition, among OCP users in the setting of bacterial vaginosis, a finding that is mechanistically consistent with our observations. Although the consensus from the literature suggests no association between OCP use and HIV risk \[[@R3]\], the reduction in bacterial vaginosis among OCP users and differences in OCP adherence may have diluted any significant results. In the context of the demonstrated effect-modification potential of bacterial vaginosis reported here, re-evaluation of those findings, if possible, is warranted.

The prevalence of bacterial vaginosis is variable based on the clinical setting and may vary by race and behavioral practices \[[@R39]\]. Although the prevalence may be underestimated as many women are asymptomatic, the greatest burden of bacterial vaginosis is noted in sub-Saharan Africa \[[@R40]\]. Further, the sensitivity and specificity of clinical techniques are variable in the diagnosis of bacterial vaginosis. For example, using Amsel\'s criteria with a wet-prep, which can be done easily as a point-of-care approach, yet is only about 70% sensitive for bacterial vaginosis \[[@R41]\]. The presence of clue cells on wet-prep, is highly sensitive and specific for bacterial vaginosis \[[@R42]\]. Nugent scores from a Gram stain, currently considered the gold standard for diagnosis for bacterial vaginosis diagnosis, may have greater sensitivity, but can be subject to variability in interpretation. Utilizing more sensitive microbiome techniques, such as 16s gene rRNA sequencing, offers an opportunity to understand the microenvironment at the level of specific microbial species and define microbial diversity with more specific methodology. Although historically symptomatic bacterial vaginosis has been attributed to *Gardnerella vaginalis*, these newer technologies have identified other bacteria associated with dysbiotic vaginal microbial states including Leptotrichia/Sneathia, Atopobium vaginae, Megasphaera sp., and members of Clostridiales sometimes referred to as bacterial vaginosis-associated bacteria (BVAB) \[[@R11],[@R43]--[@R45]\]. Further, as recent studies have suggested that specific microbacteria in the vaginal environment may have a differential impact on the local immune environment and HIV risk \[[@R45]\], it is important to explore this interaction using these more sensitive techniques.

The present study has several notable limitations. Our biggest limitation is the small number of women using contraception who seroconverted with bacterial vaginosis detected. Although even with this reduced power, we find a significant association; the stability of this finding weighs heavily on a small number of observations. Even during the years when we conducted routine examinations every 3 months, we may be missing episodes of bacterial vaginosis, because of the possible shifts between flora considered normal and flora considered intermediate or abnormal demonstrated in some studies \[[@R46]\]. This misclassification bias would primarily impact the association between contraception and HIV during the interval assessment without bacterial vaginosis detected. Additionally, we use several criteria in diagnosing bacterial vaginosis, which may increase our sensitivity while reducing the specificity of our bacterial vaginosis diagnoses. This could lead to misclassification. The generalizability of these results may be limited as this cohort consists of jointly tested and counseled HIV discordant couples who often adopt condom use following counseling with a corresponding reduction in transmission and seroconversion rates. Although we aimed to control for the impact of condom nonuse as a potential confounder, both sperm on wet-prep and self-reported unprotected sex have limitations in their ability to detect unprotected coital events, thus some degree of unmeasured confounding is possible. Given these limitations, our results should be interpreted with caution and we encourage future studies to systematically evaluate bacterial vaginosis as a modifier in future studies.

Although this evaluation begins to elucidate some of the diversity noted in epidemiologic studies, many unanswered questions remain. It is unclear if the changes attributed to bacterial vaginosis that lead to increased acquisition risk and modification of the hormone contraception--HIV association are consistent among bacterial vaginosis-symptomatic compared with asymptomatic women. It is also unknown if treatment of bacterial vaginosis will alter these associations. For example, treatment of asymptomatic bacterial vaginosis during pregnancy does reduce the risk of preterm delivery associated with bacterial vaginosis \[[@R47]\]. As bacterial vaginosis is often recurrent, exploration of the role of suppressive or periodic presumptive treatment for bacterial vaginosis on biologic and clinical outcomes is warranted \[[@R48]\]. We must leverage newer sequencing approaches to effectively explore the role of individual taxa or microbial communities of these relationships utilizing rigorous epidemiologic methodology \[[@R49]\]. And lastly, we must explore alternative explanations for the findings we report. For example, is there something else about individuals who get bacterial vaginosis that predisposes them to having increased risk with hormonal contraceptive use, such as biologic or behavioral factors?

In conclusion, our findings suggest an association between HIV acquisition and HC use, specifically OCPs and injectables, among individuals with bacterial vaginosis. Current guidelines do not restrict the use of contraceptive methods for women at high-risk for HIV. The newest WHO recommendations specifically recommend that providers discuss the potential for increased acquisition with the use of DMPA \[[@R50]\]. An individual\'s contraceptive choice is influenced by many factors, and ultimately should remain with each woman in consultation with her provider. Data on alternative contraceptive options are critical for adequate counseling on relative risks for contraceptive use. Further, the vaginal microenvironment cannot be overlooked in the field of reproductive health and HIV, especially given recent data on the impact of *G. vaginalis* on antiretroviral drug concentrations used for preexposure prophylaxis effectiveness as well the possible increased risk of human papilloma virus (HPV) with nonlactobacillus dominant flora \[[@R51],[@R52]\]. Future research is needed to further explore the interaction between bacterial vaginosis and hormonal contraception on HIV acquisition. If this interaction persists among other studies, identification of bacterial vaginosis may help tailor family planning discussions to appropriately counsel individuals on their risk. Further, periodic testing and treatment among asymptotic women at high-risk for HIV and counseling women on the symptoms of bacterial vaginosis may be important preventive strategies among reproductive aged women.
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###### 

Unadjusted seroincidence rates for linked and unlinked HIV seroconversion, stratified by time-varying bacterial vaginosis and contraceptive method use (N = 564 M+F− couples), 1994--2002.

  Contraceptive method         Number of seroconversions   Couple-years of follow-up time   Seroincidence per 100 couple-years   95% CI   
  ---------------------------- --------------------------- -------------------------------- ------------------------------------ -------- --------
  Bacterial vaginosis = YES                                                                                                               
   Nonhormonal contraception   12                          145.4                            8.3                                  4.5      14.0
   OCPs                        8                           25.8                             31.0                                 14.4     58.8
   Injectables                 2                           9.6                              20.8                                 3.5      68.8
   Implant                     0                           1.3                              0.0                                           
   *Total*                     *22*                        *182.1*                          *12.1*                               *7.8*    *18.0*
  Bacterial vaginosis = NO                                                                                                                
   Nonhormonal contraception   61                          746.9                            8.2                                  6.3      10.4
   OCPs                        15                          122.1                            12.3                                 7.1      19.8
   Injectables                 8                           82.8                             9.7                                  4.5      18.4
   Implant                     0                           3.2                              0.0                                           
  * Total*                     *84*                        *955.0*                          *8.8*                                *7.1*    *10.8*

Nonhormonal contraception, includes no method use, condom use, copper intrauterine device, and permanent method. CI, confidence interval; OCP, oral contraceptive pill.

###### 

Descriptive analyses and *P* values from unadjusted associations (from Cox models) between covariates and time to linked and unlinked HIV seroconversion, stratified by time-varying bacterial vaginosis status (*N* = 564 M+F− couples), 1994--2002.

                                                                                                       Bacterial vaginosis = yes           Bacterial vaginosis = no                                                                                                 
  ---------------------------------------------------------------------------------------------------- --------------------------- ------- -------------------------- ------- ------- ------- ---------- ------- ------- ------- ------- ------- ------- ---------- ----------
  Baseline covariates (*n* intervals, % intervals)                                                                                                                                                                                                                  
   Man, age (mean, SD)                                                                                 33.79                       8.27    33.92                      8.34    30.05   4.74    0.068      34.84   8.03    34.86   8.03    33.92   7.88    0.302      
   Woman, age (mean, SD)                                                                               27.30                       7.92    27.46                      7.97    22.68   4.64    0.014      27.83   7.38    27.87   7.40    26.35   6.61    0.083      0.528
   Years cohabiting (mean, SD)                                                                         7.35                        7.09    7.44                       7.17    4.73    3.31    0.118      8.36    7.00    8.37    7.02    7.55    6.10    0.323      0.153
   Monthly family income (mean, SD)                                                                    56.19                       60.34   56.94                      61.02   34.81   29.73   0.086      58.84   69.48   58.81   69.73   60.11   58.30   0.950      0.478
   Woman reads Nyanja                                                                                                                                                                                                                                               0.027
    Yes, easily                                                                                        107                         17%     105                        17%     2       9%      0.332      831     24%     815     24%     16      19%     0.331      
    No/with difficulty                                                                                 541                         83%     521                        83%     20      91%                2704    76%     2636    76%     68      81%                
    Number of previous pregnancies (mean, SD)                                                          3.84                        2.94    3.89                       2.96    2.57    1.96    0.082      3.97    2.81    3.98    2.83    3.71    2.14    0.471      0.68
    Number of sex partners in last year (mean, SD)                                                     1.09                        0.41    1.10                       0.41    1.05    0.22    0.234      1.03    0.34    1.03    0.33    1.06    0.45    0.431      \<.0.001
    Log viral load of positive partner, log10 copies/ml (mean, SD)[^a^](#TF2-1){ref-type="table-fn"}   4.91                        0.73    4.90                       0.73    5.14    0.57    0.187      4.91    0.74    4.91    0.74    5.04    0.66    0.132      0.873
  Time-varying covariates (*N* intervals, % interval)                                                                                                                                                                                                               
   Contraceptive method                                                                                                                                                                                                                                             
    Nonhormonal contraception                                                                          517                         80%     505                        81%     12      55%                2708    77%     2647    77%     61      73%                
    Implant                                                                                            2                           0%      2                          0%      0       0%      n/a        15      0%      15      0%      0       0%      n/a        0.0157
    Injectables                                                                                        33                          5%      31                         5%      2       9%      0.130      340     10%     332     10%     8       10%     0.761      0.009
    OCPs                                                                                               96                          15%     88                         14%     8       36%     0.004      472     13%     457     13%     15      18%     0.312      0.298
   Study interval time from enrollment                                                                                                                                                                                                                              0.641
    0--3 months                                                                                        18                          3%      13                         2%      5       23%     \<.0.001   100     3%      88      3%      12      14%     \<.0.001   
    \>3 months                                                                                         630                         97%     613                        98%     17      77%                3435    97%     3363    97%     72      86%                
   Pregnant during interval                                                                                                                                                                                                                                         0.554
    Yes                                                                                                76                          12%     74                         12%     2       9%      0.733      382     11%     370     11%     12      14%     0.312      
    No                                                                                                 566                         88%     546                        88%     20      91%                3107    89%     3035    89%     72      86%                
   Sex with study partner with a condom in past 3 months                                                                                                                                                                                                            0.057
    Yes                                                                                                494                         76%     474                        76%     20      91%     0.126      2884    82%     2818    82%     66      79%     0.572      
    No                                                                                                 154                         24%     152                        24%     2       9%                 648     18%     630     18%     18      21%                
   Sex with study partner without a condom in past 3 months                                                                                                                                                                                                         0.026
    Yes                                                                                                288                         44%     278                        44%     10      45%     0.917      1335    38%     1293    38%     42      50%     0.081      
    No                                                                                                 360                         56%     348                        56%     12      55%                2197    62%     2155    63%     42      50%                
   Sperm present on wet-prep                                                                                                                                                                                                                                        \<.0.001
    Yes                                                                                                122                         24%     117                        24%     5       31%     0.958      474     17%     459     16%     15      21%     0.211      
    No                                                                                                 377                         76%     366                        76%     11      69%                2390    83%     2333    84%     57      79%                
   Vaginal discharge                                                                                                                                                                                                                                                \<0.001
    Yes                                                                                                90                          14%     86                         14%     4       18%     0.462      311     9%      300     9%      11      13%     0.169      
    No                                                                                                 558                         86%     540                        86%     18      82%                3253    91%     3180    91%     73      87%                
   Vaginal inflammation on exam                                                                                                                                                                                                                                     0.522
    Yes                                                                                                21                          3%      18                         3%      3       14%     0.044      92      3%      89      3%      3       4%      0.664      
    No                                                                                                 616                         97%     597                        97%     19      86%                3324    97%     3243    97%     81      96%                
   Candida                                                                                                                                                                                                                                                          0.890
    Yes                                                                                                129                         20%     121                        19%     8       36%     0.068      635     18%     614     18%     21      25%     0.081      
    No                                                                                                 519                         80%     505                        81%     14      64%                2865    82%     2802    82%     63      75%                
   STI                                                                                                                                                                                                                                                              \<.0.001
    Yes                                                                                                99                          15%     95                         15%     4       18%     0.368      202     6%      191     6%      11      13%     0.004      
    No                                                                                                 549                         85%     531                        85%     18      82%                3333    94%     3260    94%     73      87%                
   BIA of women                                                                                                                                                                                                                                                     0.037
    Yes                                                                                                52                          8%      47                         8%      5       23%     0.048      254     7%      238     7%      16      19%     0.001      
    No                                                                                                 589                         92%     572                        92%     17      77%                3169    93%     3101    93%     68      81%                
   Genital ulceration in past three months                                                                                                                                                                                                                          0.106
    Yes                                                                                                135                         21%     127                        20%     8       36%     0.085      730     21%     707     20%     23      27%     0.071      
    No                                                                                                 513                         79%     499                        80%     14      64%                2805    79%     2744    80%     61      73%                

Nonhormonal contraception includes no method use, condom use, copper intrauterine device, and permanent method. BIA, bilateral inguinal adenopathy; OCP, oral contraceptive pill; SD, standard deviation; STI, sexually transmitted infections such as gonorrhea and/or chlamydia based on purulent endocervical discharge and/or trichomonas based on wet-prep.

^a^Viral load collection began in 1999.

###### 

Multivariate models of hormonal contraception use and time to linked or unlinked HIV seroconversion, stratified by time-varying bacterial vaginosis status (*N* = 564 M+F− couples), 1994--2002.

                              Bacterial vaginosis = yes   Bacterial vaginosis = no                                            
  --------------------------- --------------------------- -------------------------- -------- ------- ------- ------- ------- -------
  Nonhormonal contraception   Ref                                                                     ref                     
  Implant                     n/a                                                                     n/a                     
  Injectables                 6.546                       1.135                      37.767   0.036   1.348   0.637   2.853   0.435
  OCPs                        5.196                       1.681                      16.062   0.004   1.360   0.764   2.422   0.296

Nonhormonal contraception includes no method use, condom use, copper intrauterine device, and permanent method. aHR, adjusted hazards ratio; CI, confidence interval; ref: reference; n/a: not applicable; OCP, oral contraceptive pill; SD, standard deviation.

^a^Controlling for woman\'s age (per year increase), vaginal inflammation of woman in past 3 months, and time interval since enrollment (0--3 versus \>3 months).

^b^Controlling for inflammatory STI in the past 3 months, bilateral inguinal adenopathy in past 3 months, and time interval since enrollment (0--3 versus \>3 months).
